Gravity Analytica

Wave Life Sciences to Present at Upcoming Investor Conferences

WVE 11.26.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-12-03

Name of Upcoming Event:7th Annual Evercore HealthCONx Conference

Date of Upcoming Event:2024-12-04

Name of Upcoming Event:Citi 2024 Global Healthcare Conference

Full Press Release SEC Filings Our WVE Tweets

About Gravity Analytica

Recent Filings

CAMBRIDGE, Mass.,Nov. 26, 2024(GLOBE NEWSWIRE) --Wave Life Sciences Ltd.(Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced thatPaul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December.

7thAnnualEvercore HealthCONx ConferenceDate:Tuesday, December 3, 2024Analyst-led fireside chat:3:00 p.m. ET

Citi 2024 Global Healthcare ConferenceDate:Wednesday, December 4, 2024“Neuromuscular Disorders” panel:1:00 p.m. ET

Live webcasts of these presentations can be accessed by visiting “Investor Events” on the Investor Relations section of theWave Life Scienceswebsite:https://ir.wavelifesciences.com/events-publications/events. A replay of these presentations will be archived and available on the site for a limited time following the event.

About Wave Life SciencesWave Life Sciences(Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM^®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered inCambridge, MA.For more information on Wave’s science, pipeline and people, please visitwww.wavelifesciences.comand follow Wave onX(formerly Twitter) andLinkedIn.

Investor Contact:Kate Rausch+1 617-949-4827krausch@wavelifesci.com

Media Contact:Alicia Suter+1 617-949-4817asuter@wavelifesci.com

Source: Wave Life Sciences USA, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com